RetiSpec is very proud to be featured in September's issue of Scientific American exploring how eye tests can help to diagnose Alzheimer's disease
We are a medical imaging company building advanced Artificial Intelligence for the detection of neurodegenerative diseases.
RETISPEC IS
Affordable non-invasive eye exam using Retispec’s technology with existing ophthalmic equipment takes an image of the retina.
SIMPLE
NON-INVASIVE
AFFORDABLE
EXISTING EQUIPMENT
RETISPEC IS
Retispec’s Device captures images with a broad spectrum of information providing the basis for detailed and precise analysis.
ACCURATE
Our Artificial Intelligence compares the biological signatures associated with neurodegenerative diseases and can identify those early signs, years before they can be detectable by standard clinical methods.
RETISPEC IS
INTELLIGENT
Our Goal
We believe a better future for Alzheimer’s patients starts with the ability to diagnose it early on
Today, there is no way to make a definitive early diagnosis of Alzheimer’s disease.
RetiSpec is on track to provide a new way to detect the disease early; providing clarity to patients and their loved ones as well as new ways for clinicians and researchers to determine what treatments are effective.
Impact
Retispec is a revolutionary non-invasive tool for early affordable detection of Alzheimer’s Disease.
RetiSpec uses hyperspectral camera technology combined with AI that non-invasively looks for distinctive signs of Alzheimer’s as well as multiple other diseases like Parkinson’s, Vascular Dementia, and ALS.
If we can diagnose faster, we can treat it better, and help to find a cure sooner.
“I have had the pleasure of working with RetiSpec in the capacity of Scientific Consultant and Site PI since 2020 and am impressed with the potential of their hyperspectral imaging technology to support early diagnosis of Alzheimer’s disease in a manner that is affordable and scalable. The RetiSpec team is innovative, collaborative, and pragmatic, and is moving AD biomarker science forward in an exciting direction. Retinal imaging holds promise for clinicians, patients, and those involved in drug development to pre-screen and/or predict cerebral amyloidosis in a non-invasive manner within the clinic setting.”
Dr. Sharon Cohen
Neurologist and Medical Director, Toronto Memory Program